Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel/Irinotecan Consolidation or Salvage in Gastric Cancer
NCT00166881Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2000
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and irinotecan in gastric cancer (GC), sponsored by National Taiwan University Hospital. Primary endpoint: Overall Survival at 5 years. Started Jun 2000; status: completed.
02
Drugs
docetaxelirinotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00166881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166881.